Impax Labs launches generic version of Zomig

Impax Labs says it is now selling generic versions of migraine drug Zomig

Associated Press

HAYWARD, Calif. (AP) -- Impax Laboratories Inc. said Friday it is now selling a generic version of the migraine drug Zomig.

Impax is now selling a low-cost generic version of Zomig tablets and orally disintegrating Zomig tablets in two strengths. Zomig, or zolmitriptan, is available in tablet and nasal spray form and as tablets that will disintegrate and can be taken without liquid.

Impax said U.S. sales of the tablet and disintegrating tablet forms totaled $196 million over the 12 months ended in April.

The company gained the U.S. marketing rights to Zomig in 2012 as part of a deal with AstraZeneca PLC. Impax gets the profits from U.S. sales of Zomig and makes royalty payments to AstraZeneca.

Shares of Impax Laboratories gained 2 cents to $18.66 in morning trading.